Closing the Gap Created by Clinical Inertia
PROGRAM DESCRIPTION The prevalence of T2DM in the United States is 29.1 million and it is the seventh leading cause of death and a major cause of morbidity, including microvascular, ...
The prevalence of T2DM in the United States is 29.1 million and it is the seventh leading cause of death and a major cause of morbidity, including microvascular, macrovascular, cerebrovascular, and peripheral vascular disease complications. Clinicians face several challenges in helping patients with T2DM reach their glycemic goals, including an increasing armamentarium which gives rise to confusion regarding proper selection and sequence, multiple sets of available evidence-based guidelines, and “clinical inertia” – the failure to close the gap between best practice and the patient’s usual level of care. The goal of this symposium is to increase awareness among clinicians of the challenges in reaching T2DM glycemic targets, to review the clinical guidelines for T2DM treatment using an array of antihyperglycemic agents, and to present evidence on emerging basal insulin/GLP-1RA fixed-ratio combination products.
Upon completion of this activity, participants should be able to:Outline the stepwise approach to T2DM treatment as recommended by current ADA/EASD and AACE/ACE guidelinesList potential barriers to treatment escalation in T2DM and the role of clinical inertia in reaching glycemic targetsDescribe the complementary actions of basal insulin and GLP-1RA inhibitors in treating T2DMIdentify the role of emerging fixed-ratio basal insulin/GLP-1RA products in the treatment of patients with T2DM
I'm interested in this
Share with others
Write the first review
Share with others